The proposal to accumulate the stake from minority shareholders in an all money deal is a strategic funding geared toward to increasing geographic footprint in South Africa, Natco mentioned on Wednesday. Founded in 1890, AIHL has a various product portfolio, from generic and branded formulations, critical-care hospital merchandise to shopper and home-care merchandise. It operates throughout 4 segments -prescription, shopper, OTC and hospitals.
The acquisition is predicted to be accomplished by 2025. Post-acquisition, AIHL will proceed to function as a personal South African enterprise with Bidvest holding 64.25% and Natco 35.75%, together with a previous held 0.80% stake, within the firm. Post-transaction, Natco will consolidate 35.75% of AIHL internet earnings in its monetary outcomes. AIHL clocked income of $536 million within the monetary 12 months June 2024 and revenue after tax of $45 million.
“Adcock Ingram is a good pharmaceutical firm with well-recognised manufacturers and merchandise and maintains a number one place within the South African pharmaceutical market. The proposed transaction will present Natco Pharma with a well-established entry into the Southern African market. It can even enable us to faucet into new income streams and increase our footprint in one of many largest and rising rising markets, whereas offering a gateway to the African continent,” CEO and Vice-Chairman Rajeev Nannapaneni mentioned.
Besides the acquisition, Natco Pharma Board additionally accepted a proposal to incorporate an entirely owned subsidiary in South Africa with an funding of as much as Rs.2,100 crore by this 12 months to enter new geographies for progress and elevated profitability. It additionally accepted a proposal to liquidate wholly owned subsidiary Time Cap Overseas (TCOL), and straight maintain the funding in step down subsidiary NatcoFarma do Brasil.
Natco shares closed 2.01% increased at ₹1,034.75 apiece on the BSE.
Published – July 23, 2025 10:55 pm IST
No Comment! Be the first one.